ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1700

IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease

Jieqiong Li1 and Wen Zhang2, 1Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 2Peking Union Medical College Hospital, Beijing, China

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, B-Lymphocyte, Cell-signalling molecules, cytokines, innate immunity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: To explore the phenotype and role of gamma delta (γδ) T cells in the pathogenesis of IgG4-related disease (IgG4-RD), focusing on the effect on plasmablasts differentiation and immunoglobulin production.

Methods: Peripheral γδ T cells, chemokine receptor expression, intracellular cytokines expression, and transcription factors expression were quantified by flow cytometry and qRT-PCR. The infiltration of Vδ2 T cells, and locations of B cells and chemokine receptors within the tissue involved were examined by immunofluorescence. Transwell assay was used to detect the chemotactic rate of Vδ2 T cell to specific chemokine. CD19+ B cells were cultivated with the expanded Vδ2 T cells or Vδ2 T-SNs. B cell subsets and immunoglobulin production were assessed by flow cytometry and ELISA. The effects of IL-21, JAK inhibitor, and STAT3 inhibitor on Vδ2 T cells were determined by flow cytometry.

Results: Proportions of γδ T cells, especially Vδ2 T cells were significantly decreased in the peripheral blood of patients with active IgG4-RD. Vδ2 T cells from IgG4-RD produced high levels of Th2-type cytokines (IL-4, IL-5, IL-9, IL-13), IL-21R, GATA3, Blimp-1, and CCR7. But the expressions of Th1-type cytokines, CXCR5, ICOS, CD40L, and transcription factor TBX21, FOXP3, RORC, and BCL6 were similar with or not higher than healthy controls (HCs). Immunofluorescent staining revealed the accumulation of Vδ2 T cells and co-localization of Vδ2 T cells, B cells, and CCR7/CCL21 in the involved submandibular gland tissues. The migration rate of IgG4-RD Vδ2 T cells to CCL21 was higher than that of HC. In vitro, both expanded Vδ2 T cells and supernatant (SN) from active IgG4-RD patients promoted B cell differentiation into plasmablasts and immunoglobulin production. The expressions of pSTAT3 (pY705), GATA3 and Blimp-1 in Vδ2 T cells were increased in patients with IgG4-RD compared to HCs, and GATA3 expression further increased after IL-4 stimulation. And there were positive correlations among the protein levels of pSTAT3, Blimp-1, and GATA3. IL-21 stimulation promoted the expressions of pSTAT3, Blimp-1, and GATA3 in Vδ2 T cells from HCs, while JAK inhibitors (Baricitinib and Tofacitinib) and STAT3 inhibitors (S3I-201) inhibited this process. In addition, TGF-β was increased in the patients with IgG4-RD compared with HCs in the γδ T cells and its subsets, and the pro-fibrotic genes expression also increased in γδ T cells from IgG4-RD patients, including ACTA2, COL1A1, COL1A2, and COL3A1.

Conclusion: Peripheral Vδ2 T cells obtain a Th2-like phenotype in the IL-21 highexpressed microenvironment of IgG4-RD through the IL-21—STAT3—Blimp-1—GATA3 pathway, and play a role in promoting plasmablasts differentiation and immunoglobulin production. The high expression of CCR7 may contribute to its chemotaxis to the involved tissues and the interaction with B cells. JAKi and STAT3i, as well as IL-21i inhibit the Th2-like phenotypes in Vδ2 T cells mediated by IL-21-pSTAT3 pathway, thereby opening up new therapeutic approaches in IgG4-RD.

Supporting image 1

Circulating Vδ2 T cells were decreased and presented an intrinsic Th2-like phenotype in IgG4-RD.

Supporting image 2

Vδ2 T cells from IgG4-RD patients provides B-cell help through type 2 immune response.

Supporting image 3

IL_21–STAT3–Blimp_1 circuit promotes GATA3 expression in Vδ2 T cells, which is inhibited by JAKi/STAT3i. Tofa1, Tofacitinib (10 nM); Tofa2, Tofacitinib (100 nM); Bari, Baricitinib (300 nM); S3I, STAT3 inhibitor S3I_201 (10 uM).


Disclosures: J. Li, None; W. Zhang, None.

To cite this abstract in AMA style:

Li J, Zhang W. IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/il-21-stat3-pathway-mediated-th2-like-v%ce%b42-t-cells-promote-plasmablasts-differentiation-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-21-stat3-pathway-mediated-th2-like-v%ce%b42-t-cells-promote-plasmablasts-differentiation-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology